RxDoctor Payments Data

Yessar Hussain, MD

Neuromuscular Medicine · Austin, TXNPI 1982852166

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (48.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 58.2% of the total. Reporting peaked in 2020 at $42,504 and has fallen 92.3% since, to $3,252 in 2025.

$126,535in general payments, 2019–2025

Across 105 payments — averaging $1205.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$74K
  • AstraZeneca$29K
  • Argenx US, Inc.$13K
  • CSL Behring$6K
  • Amgen$5K
  • AbbVie$146
  • plus $726 from 14 others
$6,643,446in research payments, 2019–2025

Across 1,563 payments — averaging $4250.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Argenx US, Inc.$1.7M
  • UCB SA$1.2M
  • Alnylam Pharmaceuticals Inc.$523K
  • AstraZeneca$514K
  • Regeneron$484K
  • Amgen$393K
  • plus $1.9M from 22 others

What the payments were for

  • Consulting fees$42,17833%
  • Speaking & faculty fees$61,54449%
  • Travel & lodging$20,46316%
  • Food & beverage$1,9612%
  • Education$3900%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuromuscular medicine providers in Texasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,718,974
Medicare patients
603
Services billed
33,996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AmvuttraVutrisiran Sodium17$1,936,589
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5057$702,922
GammakedImmune Globul G/Gly/Iga Avg 4622$308,878
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5018$200,284
Pyridostigmine Bromide30$1,407
Gabapentin49$701
Pregabalin13$641
Sodium Chloride0.9 % Sodium Chloride24$338
Prednisone34$292
Nortriptyline Hcl15$283
Diazepam13$130
Dexamethasone Sodium Phosphate15$68

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alnylam Pharmaceuticals Inc.Amvuttra$73,651$1,936,58917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in Texason file to place this against a meaningful peer group, so we don't.

Other neuromuscular medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →